A new funding dataset reports biopharma money raised through late August 2026, providing a read on capital availability across public, private, and other financing channels. The figure tracks year-to-date totals and compares them with prior years’ raised capital. For investors and operators, the snapshot provides context for deal-making intensity and pipeline financing conditions as major programs continue to progress from early clinical stages into late-stage registrational work.